ATRA
Atara Biotherapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Last price
9.70
▲ 0.32 (3.41%)
MARKET · —
Price
Open
9.11
Prev close
9.38
Day high
9.84
Day low
9.15
Volume
27.06K
Market cap
$97.37M
P/E (TTM)
—
52W range
3.92 – 19.15
Trailing performance
Returnvs SPY
1W
+19.90%
+21.3%
1M
+18.73%
+15.0%
3M
+3.85%
+0.8%
6M
+132.06%
+121.0%
YTD
-46.38%
-58.7%
1Y
-17.52%
-37.5%
3Y
-77.04%
-151.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$97.37M
Enterprise value$97.37M
Revenue (TTM)$6.19M
Gross profit$4.66M
EBITDA$-11.06M
Net income$-16.69M
EPS (TTM)$-1.54
Free cash flow$-12.52M
Total cash$9.87M
Total debt$9.88M
Book value / share$-3.92
Shares outstanding10.04M
Float4.73M
Short % of float8.49%
Dividend yield—
Beta (5Y)0.10
Valuation & profitability ratios
Trailing P/E—
Forward P/E6.20
PEG ratio—
Price / sales—
Price / book—
EV / revenue15.72
EV / EBITDA-8.81
Gross margin75.27%
Operating margin-627.46%
Profit margin-269.42%
Return on equity—
Return on assets-24.14%
Debt / equity—
Current ratio1.98
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $120.77M | $128.94M | $8.57M | $63.57M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $32.69M | -$85.40M | -$276.13M | -$228.30M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.25 | -0.32 | -28.0% |
| Mar 2026 | -0.22 | — | — |
| Dec 2025 | -0.10 | -0.35 | -238.7% |
| Sep 2025 | -0.67 | -0.32 | +51.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.33 | 1 | $300.00K | -91.3% |
| Next quarter | -0.32 | 1 | $350.00K | -78.1% |
| Current year | -1.27 | 1 | $1.77M | -98.5% |
| Next year | 1.11 | 3 | $45.65M | +2,474.7% |
Analyst targets & ownership
Mean target$13.67
High target$18.00
Low target$10.00
Implied upside40.89%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders15.19%
Held by institutions57.67%
Institutions holding46
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+715.88K
Net buying
Buy transactions
8
1.04M shares
Sell transactions
5
326.20K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
1.52M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 22, 26 | REDMILE GROUP, L.L.C. Unknown |
— | 195.21K | — | Indirect |
| Jun 11, 26 | CHERRY BRIAN N Director |
STOCK | 24.00K | $0 | Direct |
| Jun 9, 26 | FUST MATTHEW K. Director |
STOCK | 12.00K | $0 | Direct |
| Jun 9, 26 | HEIDEN WILLIAM K Director |
STOCK | 12.00K | $0 | Direct |
| Jun 9, 26 | CIONGOLI GREGORY AUSTIN Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 12.00K | $0 | Direct |
| May 18, 26 | NGUYEN ANHCO T Chief Executive Officer |
SELL | 5.24K | $47.84K | Direct |
| May 18, 26 | GRANT-HUERTA YANINA Officer |
SELL | 2.41K | $22.04K | Direct |
| May 7, 26 | PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security |
SELL | 313.45K | $3.17M | Indirect |
| May 7, 26 | ECOR1 CAPITAL, L.L.C. Beneficial Owner of more than 10% of a Class of Security |
BUY | 507.41K | $4.74M | Indirect |
| Mar 17, 26 | PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security |
CONVERSION | 259.16K | $26 | Indirect |
| Mar 9, 26 | GRANT-HUERTA YANINA Officer |
STOCK | 20.30K | $0 | Direct |
| Mar 2, 26 | NGUYEN ANHCO T Chief Executive Officer |
SELL | 3.00K | $15.24K | Direct |
| Mar 2, 26 | GRANT-HUERTA YANINA Officer |
SELL | 2.10K | $10.69K | Direct |
| Jan 12, 26 | PANACEA INNOVATION LTD Beneficial Owner of more than 10% of a Class of Security |
SELL | 80.55K | $489.02K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADIUMENTUM CAPITAL FUND I LP |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Award(Grant) |
CHERRY BRIAN N |
Director | 62.32K | Stock Award(Grant) |
CIONGOLI GREGORY AUSTIN |
Director and Beneficial Owner of more than 10% of a Class of Security | 1.22M | Stock Award(Grant) |
ECOR1 CAPITAL, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
HYLLENGREN ERIC J |
Chief Operating Officer | 56.23K | Sale |
NGUYEN ANHCO T |
Chief Executive Officer | 137.84K | Sale |
PANACEA INNOVATION LTD |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
PANACEA VENTURE |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
REDMILE GROUP, L.L.C. |
Unknown | — | Conversion of Exercise of derivative security |
TOUCHON PASCAL |
Director | 77.95K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
8.91
+8.82% from price
SMA 20
8.59
+12.91% from price
SMA 50
9.29
+4.37% from price
SMA 100
8.28
+17.13% from price
SMA 200
8.97
+8.14% from price
EMA 12
8.94
+8.45% from price
EMA 26
8.86
+9.51% from price
EMA 50
8.86
+9.50% from price
RSI (14)
59.2
Neutral
MACD (12,26,9)
0.09
Hist 0.18
ATR (14)
0.73
7.50% of price
Realised vol 30D
73.1%
Annualised
Bollinger upper
9.67
20, 2σ
Bollinger lower
7.52
20, 2σ
50 / 200 cross
Golden
9.29 vs 8.97
Trend bias
Above 200
+8.14%
Risk profile
Beta vs SPY
1.35
More volatile than market
Correlation to SPY
0.12
Largely independent
Realised vol 30D
73.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-76.9%
Peak to trough
Max drawdown 5Y
-99.2%
Peak to trough
ATR 14
0.73
7.50% of price
Beta (reported)
0.10
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Atara Biotherapeutics: Q2 Earnings Snapshot
Associated Press · 10d ago
Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress
Business Wire · 10d ago
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
Investor's Business Daily · 66d ago
Atara Biotherapeutics Announces Changes to Its Board of Directors
Business Wire · 71d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.